Searchable abstracts of presentations at key conferences in endocrinology

ea0056p806 | Pituitary - Clinical | ECE2018

Association between prolactin level and tumor size reduction at 3 months after cabergoline treatment in patients with macroprolactinoma

Kim Daham , Lee Youngki , Park Se Hee , Park Kyeong Hye , Ryong Ku Cheol , Kim Sun Ho , Lee Eun Jig

Objectives: Prolactin (PRL) normalization after 3 months of Cabergoline (CAB) treatment are useful predictors of responsiveness in patients with prolactinoma. However, differences within the PRL normalization cut-off value have not been identified.Methods: We reviewed the medical records of patients with prolactinomas who were treated with CAB as a primary drug at Severance Hospital. We included patients who had a full dataset of pituitary hormone assays...

ea0056p809 | Pituitary - Clinical | ECE2018

Clinical parameters to distinguish silent corticotroph adenomas from other non-functioning pituitary adenomas

Kim Daham , Ku Cheol Ryong , Park Se Hee , Park Kyeong Hye , Moon Ju Hyung , Kim Eui Hyun , Kim Sun Ho , Lee Eun Jig

Silent corticotroph adenomas (SCAs) are difficult to distinguish from other non-functioning pituitary adenomas (NFPAs) preoperatively. This study assessed the preoperative clinical parameters associated with SCAs. After excluding patients with increased 24-h urinary free cortisol, 341 patients who underwent surgery for NFPAs during 2011–2016 with available preoperative combined pituitary function test (CPFT) and immunohistochemical staining results were enrolled. The pati...